KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Biomarin Pharmaceutical (BMRN) Depreciation and Depletion (2016 - 2025)

Biomarin Pharmaceutical (BMRN) has disclosed Depreciation and Depletion for 16 consecutive years, with $13.1 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Depreciation and Depletion rose 12.93% year-over-year to $13.1 million, compared with a TTM value of $48.5 million through Dec 2025, up 4.08%, and an annual FY2025 reading of $48.5 million, up 4.08% over the prior year.
  • Depreciation and Depletion was $13.1 million for Q4 2025 at Biomarin Pharmaceutical, up from $10.6 million in the prior quarter.
  • Across five years, Depreciation and Depletion topped out at $14.1 million in Q1 2025 and bottomed at $8.7 million in Q3 2022.
  • Average Depreciation and Depletion over 5 years is $11.0 million, with a median of $10.8 million recorded in 2023.
  • Peak annual rise in Depreciation and Depletion hit 145.72% in 2021, while the deepest fall reached 41.91% in 2021.
  • Year by year, Depreciation and Depletion stood at $10.4 million in 2021, then dropped by 16.35% to $8.7 million in 2022, then grew by 22.99% to $10.7 million in 2023, then grew by 8.41% to $11.6 million in 2024, then grew by 12.93% to $13.1 million in 2025.
  • Business Quant data shows Depreciation and Depletion for BMRN at $13.1 million in Q4 2025, $10.6 million in Q3 2025, and $10.7 million in Q2 2025.